Please assess the completion status of the following clinical trial:

Trial Title: Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Provide informed consent from a competent custodial parent or guardian with legal capacity to execute a local Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved consent. In addition, informed assent will be sought from capable subjects, in accordance with the directive of the institution's IRB/IEC and all other local requirements.~2. Be male and ≤17 years of age at the time of treatment, for retrospective and partial prospective/retrospective subjects, or at the time of parental/guardian consent and, where appropriate, subject assent, for prospective subjects.~3. Have a confirmed diagnosis of CALD as defined by abnormal VLCFA profile and cerebral lesion on brain MRI.~4. Depending on the cohort, the subject must:~   * Be scheduled for allo-HSCT evaluation at a study site (prospective cohort only),~  * Have received an allo-HSC infusion and be consented in time to complete the Month 24 Visit on study (partial prospective/retrospective cohort only), or~  * Have received their most recent allo-HSC infusion on or after January 1, 2013 (retrospective cohort only).~Exclusion Criteria:~1. Previous treatment with a gene therapy product.~2. Receipt of an experimental transplantation procedure.

- Gender: MALE
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Allo-HSCT prospective (Type: None): Subjects who will be consented before they received an allo-HSC infusion. They will be consented and enrolled on the study during the Screening Period.
- Allo-HSCT partial prospective/retrospective (Type: None): Subjects who will be consented after they received an allo-HSC infusion but before they reach 24 months post-infusion on study. Subjects in this cohort will participate prospectively in at least the Month 24 Visit in order to obtain prospective on-study data for this and all visits after Month 24
- Allo-HSCT retrospective (Type: None): Subjects who received an allo-HSC infusion on or after January 1, 2013 and died before study data collection.

Based on this trial design, predict the completion outcome and termination type (if applicable).